Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications

British Journal of Clinical Pharmacology

Volumn 56, Issue 6, 2003, Pages 588-599

  Labiris, N R ^a,b   Dolovich, M B ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b St Joseph's Healthcare   (Canada)

Author keywords

Administration; Aerosol; Inhalation; Lung; Review

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL;

AEROSOL; AIRBORNE PARTICLE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GEOMETRY; HUMAN; HUMIDITY; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG CIRCULATION; LUNG CLEARANCE; LUNG DEPOSIT; MUCOCILIARY CLEARANCE; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMIC DISEASE;

ABSORPTION; ADMINISTRATION, INHALATION; AEROSOLS; BRONCHI; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS;

EID: 0344513087     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01892.x     Document Type: Review

References (72)

1. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999; 12(Suppl 1): s9-s17.
2. CPS. Compendium of pharmaceuticals and specialties, 35th edn. Ed Welbanks L. Ottawa, Ontario: Canadian Pharmacists Association, 2000.
3. Byron PR. Inhalation devices. In The pharmacy and pharmacotherapy of asthma, eds D'Arcy PF, Mcelnay JC. Chichester: Ellis Horwood Ltd, 1989; 47-69.
4. Ruffin RE, Dolovich MB, Wolff RK, Newhouse MT. The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis 1978; 117: 485-492.
5. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985; 132: 541-547.
6. Mak JCW, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990; 141: 1559-1568.
7. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505-1510.
8. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10: 292-300.
9. Johnson MA, Newman SP, Bloom R, Talaee N, Clarke SW. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy Pulmonary Deposition Chest 1989; 96: 6-10.
10. Rees PJ, Clark TJ, Moren F. The importance of particle size in response to inhaled bronchodilators. Eur J Resp Dis 1982; 119(Suppl): 73-78.
11. Zanen P, Go LT, Lammers J-WJ. The optimal particle size for β-adrenergic aerosols in mild asthmatics. Int J Pharmaceutics 1994; 107: 211-217.
12. Zanen P, Go LT, Lammers J-WJ. Optimal particle size for β2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996; 51: 977-980.
13. Baskin ML, Abd AG, Ilowite JS. Regional deposition of aerosolized pentamidine. Effects of body position on breathing pattern. Ann Intern Med 1990; 113: 677-683.
14. Gerrity TR, Garrard CS, Yeates DB. Theoretical analysis of sites of aerosol deposition in the human lung. Chest 1981; 80(Suppl 6): 898-901.
15. Baltimore RS, Christie CDC, Walker Smith GJ. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis 1989; 140: 1650-1661.
16. Potts SB, Roggli VL, Spock A. Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Pediatric Pathol Lab Med 1995; 15: 707-721.
17. Alderson PO, Secker-Walker RH, Stominger DB, et al. Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr 1974; 84: 479-484.
18. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987; 136: 1445-1449.
19. Anderson PJ, Blanchard JD, Brain JD, Feldman HA, McNamara JJ, Heyder J. Effect of cystic fibrosis on inhaled aerosol boluses. Am Rev Respir Dis 1989; 140: 1317-1324.
20. Wolff RK. Safety of inhaled proteins for therapeutic use. J Aerosol Med 1998; 11: 197-219.
21. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994; 7: 49-75.
22. Concepts of pulmonary physiology. In Essentials of respiratory disease, 3rd edn, eds Cole RB, Mackay AD. New York: Churchill Livingstone, 1990; 49-60.
23. Patton JS. Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery Rev 1996; 19: 3-36.
24. Farr ST, Gonda I, Licko V. Physicochemical and physiological factors influencing the effectiveness of inhaled insulin. In Respiratory drug delivery, 6th edn, eds Dalby RN, Byron PR, Farr ST. Buffalo Grove, IL: Interpharm Press Inc., 1998; 25-33.
25. Laube BL, Georgopoulos A, Adams GKI. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 1993; 269: 2106-2109.
26. Jendle JH, Karlberg BE. Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 1996; 56: 555-561.
27. Jendle JH, Karlberg BE. Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 1996; 240: 93-98.
28. Laube BL, Benedict GW, Dobs AS. Time to peak insulin level, relative bioavailability, and effect of size of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. J Aerosol Med 1998; 11: 153-173.
29. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63-72.
30. Ma JKH, Bhat M, Rojanasakul Y. Drug metabolism and enzyme kinetics in the lung. In Inhalation aerosols. Physical and biological basis for therapy, ed Lenfant C. New York: Marcel Dekker Inc., 1996; 94: 155-195.
31. Folkesson HG, Matthey MA, Westrom BR, Kim KJ, Karlsson BW, Hastings RH. Alveolar epithelial clearance of protein. J Appl Physiol 1996; 80: 1431-1445.
32. Dolovich MB, Newhouse MT. Aerosols. Generation, methods of administration, and therapeutic applications in asthma. In Allergy. Principles and practice, 4th edn, eds Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW. St Louis: Mosby Year Book, Inc., 1993; 712-739.
33. Lourenco RV, Cotromanes E. Clinical aerosols. I. Characterization of aerosols and their diagnositic uses. Arch Intern Med 1982; 142: 2163-2172.
34. Heyder J. Particle transport onto human airway surfaces. Eur J Respir Dis 1982; 63(Suppl 119): 29-50.
35. Brain JD, Blanchard JD. Mechanisms of aerosol deposition and clearance. In Aerosols in Medicine. Principles, diagnosis and therapy, 2nd edn. eds Moren F, Newhouse MT, Dolovich MB. New York: Elsevier Science Publishers (Biomedical Division), 1993; 117-156.
36. Gerrity TR. Pathophysiological and disease constraints on aerosol deposition. In Respiratory drug delivery. Ed Byron PR. Boca Raton, FL: CRC Press, Inc., 1990; 1-38.
37. Effros RM, Mason GR. Measurements of pulmonary epithelial permeability in vivo. Am Rev Resp Dis 1983; 127(Suppl): s59-s66.
38. Folkesson HG, Westrom BR, Karlsson BW. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol Scand 1990; 139: 347-354.
39. Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985; 88(Suppl): 152s-60s.
40. Phipps PR, Gonda I, Anderson SD, Bailey D, Bautovich G. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. Eur Resp J 1994; 7: 1474-1482.
41. Swift DL. Aerosols and humidity therapy: generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis 1980; 122: 71-91.
42. Ferron GA, Hornik S, Kreyling WG, Haider B. Comparison of experimental and calculated data for the total and regional deposition in the human lung. J Aerosol Sci 1985; 16: 133-143.
43. Ferron GA, Oberdörster G, Henneberg R. Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth. J Aerosol Med 1989; 2: 271-284.
44. Xu GB, Yu CP. Theoretical lung deposition of hygroscopic NaCl aerosols. Aerosol Sci Technol 1985; 4: 455-461.
45. Smaldone GC, Perry RJ, Bennett WD, Messina MS, Zwang J, Ilowite J. Interpretation of '24 hour lung retention' in studies of mucociliary clearance. J Aerosol Med 1988; 1: 11-20.
46. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur Respir J 1999; 13: 1177-1188.
47. Rossman CM, Lee RMKW, Forrest JB, Newhouse MT. Nasal ciliary ultrastructure and function in patients with primary ciliary dyskinesia compared with that in normal subjects and in subjects with various respiratory diseases. Am Rev Respir Dis 1984; 129: 161-167.
48. Isawa T, Teshima T, Hirano T, et al. Mucociliary clearance and transport in bronchiectasis: global and regional assessment. J Nucl Med 1990; 31: 543-548.
49. Robinson M, Bye PTB. Mucociliary clearance in cystic fibrosis. Pediatric Pulmonol 2002; 33: 293-306.
50. Rossman CM, Waldes OR, Sampson D, Newhouse MT. Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. Am Rev Respir Dis 1982; 126: 131-135.
51. Edsbacker S. Uptake, retention and biotransformation of corticosteroids in the lung and airways. In Inhaled steroids in asthma. Optimizing effects in the airways. Eds Schleimer RP, O'Byrne PM, Szefler SJ, Brattsand R. New York: Marcel Dekker, Inc., 2002; 213-246.
52. Summers QA. Inhaled drugs and the lung. Clin Exp Allergy 1991; 21: 259-268.
53. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD. Allometric relationship of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol 1992; 6: 235-243.
54. Martonen TB. Mathematical model for the selective deposition of inhaled pharmaceuticals. J Pharmaceut Sci 1993; 82: 1191-1199.
55. Upton RN, Doolette DJ. Kinetic aspects of drug disposition in the lungs. Clin Exp Pharmacol Physiol 1999; 26: 381-391.
56. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinetics 1994; 26: 144-160.
57. Dahl AR, Lewis JL. Respiratory tract uptake of inhalants and metabolism of xenobiotics. Annu Rev Pharmacol Toxicol 1993; 32: 383-407.
58. Barrowcliffe MPA, Jones JG, Sever PS. Pulmonary clearance of vasoactive intestinal peptide. Thorax 1986; 41: 88-93.
59. Hastings RH, Grady M, Sakuma T, Matthay MA. Clearance of different-sized proteins from the alveolar space in humans and rabbits. J Appl Physiol 1992; 73: 1310-1316.
60. Yamamoto A, Umemoir S, Muranishi S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and proteases inhibitors in rats. J Pharm Pharmacol 1994; 46: 14-18.
61. Morita T, Yamamoto A, Takakura Y, Hashida M, Sezaki H. Improvement of the pulmonary absorption of (Asu1,7)-Eel calcitonin by various protease inhibitors in rats. Pharmaceut Res 1994; 11: 909-913.
62. Lourenco RV, Loddenkemper R, Carton RW. Patterns of distribution and clearance of aerosols in patients with bronchiectasis. Am Rev Respir Dis 1972; 106: 857-866.
63. Dolovich M, Nahmias C, Coates G. Unleashing the PET. 3D imaging of the lung. In Respiratory drug delivery VII. Biological, pharmaceutical, clinical and regulatory issues relating to optimized drug delivery by aerosol, 7th edn, eds Dalby RN, Byron PR, Farr ST et al. Raleigh, NC: Serentec Press, Inc., 2000; 215-230.
64. Pavia D, Thomson ML, Clarke SW, Shannon HS. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax 1977; 32: 194-197.
65. Dolovich M, Ryan G, Newhouse MT. Aerosol penetration into the lung. Influence on airway responses. Chest 1981; 80(Suppl 6): 834-836.
66. Sanchis J, Dolovich MB, Rossman C, Newhouse MT. Lung clearance in patients with airways obstruction. Bull Physio-Path Resp 1973; 9: 325-335.
67. Dolovich MB, Sanchis J, Rossman C, Newhouse MT. Aerosol penetrance: a sensitive index of peripheral airway obstruction. J Appl Physiol 1976; 40: 468-471.
68. Laube BL, Swift DL, Wagner HN, Norman PS, Adams GKI. The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma. Am Rev Respir Dis 1986; 133: 740-743.
69. Nunn JF, ed. Applied respiratory physiology, 4th edn. London: Butterworths, 1993.
70. Deffebach ME, Charan NB, Lakshminarayan S, Butler J. The bronchial circulation. Am Rev Respir Dis 1987; 135: 463-481.
71. Ryrfeldt A. The bronchial circulation - a significant local distribution system in the lung, in inhalation therapy? J Aerosol Med 1990; 3: 165-168.
72. Dolovich MB. Aerosols. In Asthma, eds Barnes PJ, Grunstein MM. Philadelphia: Lippincott-Raven Publishers, 1997; 1349-1366.